Study guide · Medication after a heart attack

Understanding your medicines after a heart attack

As of November 18, 2026 · Leitlinienstand 2026 · about 19 min read

This page is for learning and does not replace a conversation with your doctor. After a heart attack, almost everyone gets several medicines at once. Here you will learn what each of them does, which side effects are typical and why you should never simply leave one out. As an example, you will follow Mr K., 58, who had a heart attack with a stent three months ago.

Why so many tablets?

A heart attack usually happens when a deposit in a coronary artery tears open and a blood clot forms there. The medicines afterwards act at exactly these points. They slow down the deposits, prevent new clots and relieve the heart.

The basic therapy consists of two groups. Almost everyone takes an antiplatelet drug such as aspirin and a statin to lower cholesterol for the long term. This applies even if you feel well. Depending on how well the heart pumps and on other conditions, beta blockers, ACE inhibitors or other drugs are added. Supplements such as omega-3 capsules are not part of the recommended basic therapy.

Mr K., for example, takes aspirin, ticagrelor, atorvastatin, ramipril and bisoprolol. He also has a nitro spray for emergencies. So that he and everyone treating him keep track, he has a medication plan. It lists every drug with its dose, the time to take it and the reason. In Germany, anyone who regularly takes three or more prescribed medicines is entitled to this standardised national plan. It helps emergency services, dentists and pharmacies spot interactions.

Statins: the foundation against LDL

Statins block a key enzyme of cholesterol production in the liver, called HMG-CoA reductase. The liver cell then lacks the cholesterol it would normally make itself. So it puts more LDL receptors on its surface and uses them to catch more LDL from the blood. This is how the LDL level falls.

Statins have the strongest evidence for preventing heart attacks and deaths. That is why they are the first lipid-lowering drug after a heart attack. After an acute coronary syndrome, the ESC recommends a high-intensity statin, started early in hospital. A dose counts as high intensity if it lowers LDL by at least 50 percent on average. Moderate-intensity doses manage 30 to 50 percent. How strongly a statin works for you can vary considerably, though.

When your muscles ache

The best-known side effect of statins is muscle pain or muscle weakness. In observational studies, 10 to 15 percent of users report it. In blinded trials, however, the complaints occur almost as often on placebo. In the SAMSON trial from 2020, people took a statin, a placebo or nothing at all, in turns. Complaints on the placebo tablets were almost as strong as on the statin. Around 90 percent of the symptom burden was due to expectation. This is called the nocebo effect.

When muscle complaints occur, creatine kinase, CK for short, is measured. It is a muscle enzyme that rises when muscle cells are damaged. Without complaints, regular CK checks are not needed.

So a different dose or a different statin often helps. Doing without statins altogether is only an option after several unsuccessful attempts. Real danger is very rare. Severe muscle pain with dark urine and a CK above ten times the upper limit point to rhabdomyolysis, a serious breakdown of muscle. The statin is then stopped and kidney function is checked, because released muscle protein can damage the kidneys.

Liver values are also watched. The value ALT is measured before starting and once 8 to 12 weeks after the start or after a dose increase. Routine checks after that are not needed. A rise below three times the upper limit usually allows you to continue. Only above that is the statin paused or the dose reduced.

Statins also slightly raise the risk of diabetes. About 255 people need to take a statin for four years for one extra case of diabetes. The benefit for the heart and vessels clearly outweighs this, and people with diabetes benefit in particular.

When the statin is not enough

After an acute coronary syndrome, blood lipids are measured again after 4 to 6 weeks. This shows whether the target has been reached and whether the statin is tolerated. For people after a heart attack, the ESC sets an LDL below 55 milligrams per decilitre and a reduction of at least half.

If the statin is not enough, treatment is stepped up:

  1. A high-intensity statin at the highest dose you tolerate.
  2. Add ezetimibe if the target is not reached after 4 to 6 weeks.
  3. Add a PCSK9 inhibitor if a statin plus ezetimibe is still not enough.

The 2025 ESC focused update stresses combining drugs early after an acute coronary syndrome, often while still in hospital.

Where lipid-lowering drugs act Gut Ezetimibe slows the uptake of cholesterol Liver cell Cholesterol production Statin and bempedoic acid inhibit it Production of PCSK9 PCSK9 breaks down receptors Inclisiran slows its production LDL receptors Blood with LDL particles PCSK9 antibodies: more receptors are kept
Where lipid-lowering drugs act.

Ezetimibe blocks the absorption of cholesterol in the small intestine, both from food and from bile. Added to a statin, it lowers LDL by roughly another 21 to 27 percent. It is a tablet, also available combined with the statin in one tablet.

PCSK9 antibodies such as evolocumab and alirocumab target the protein PCSK9. Normally, this protein causes LDL receptors to be broken down. When the antibody blocks PCSK9, more receptors are kept and catch more LDL. You inject them under the skin yourself, every two weeks or once a month depending on the drug. On average they lower LDL by about 60 percent. The most common side effects are reactions at the injection site.

Inclisiran acts one step earlier. It is a small RNA that suppresses the production of PCSK9 inside the liver cell. The antibodies, by contrast, capture PCSK9 that is already in the blood. Inclisiran is injected at the start, after three months and then only every six months, so twice a year. The injection is usually given at the practice.

Bempedoic acid is a tablet. Like a statin, it blocks cholesterol production in the liver, but at an earlier enzyme. It is a precursor that only a liver enzyme activates. This enzyme is largely missing in skeletal muscle. That is why it causes muscle complaints less often. The 2025 ESC update recommends it mainly for people who cannot tolerate statins. It lowers LDL by about 20 to 30 percent, much less than the antibodies. As a side effect it can raise uric acid and favour gout.

Antiplatelet drugs: aspirin and its partners

Low-dose aspirin stops blood platelets from clumping. This makes it harder for a clot to form on deposits and on the stent. Aspirin does not dissolve existing clots, and it lowers neither cholesterol nor blood pressure. After a heart attack, aspirin is usually taken for life, mostly 75 to 100 milligrams a day.

In the first months, a second antiplatelet drug is added. This combination is called dual antiplatelet therapy: aspirin together with a P2Y12 inhibitor. This group includes clopidogrel, prasugrel and ticagrelor. They block a different receptor on the platelets than aspirin does.

  • Ticagrelor is taken in the morning and in the evening, because its effect wears off after some hours. A feeling of breathlessness is one of the most common side effects and affects more than one in ten people. Report it to your practice.
  • Prasugrel is taken once a day. After a previous stroke or TIA it is contraindicated, because the risk of brain bleeding rises. From age 75 or below 60 kilograms it is used only with caution or at a lower dose.
  • Clopidogrel is also taken once a day. It is a precursor that the liver activates mainly via the enzyme CYP2C19.

As a rule, dual antiplatelet therapy lasts twelve months. If the bleeding risk is high, the doctor may shorten it; if the risk of another heart attack is high, they may extend it. After that, one antiplatelet drug alone is usually continued for good, normally aspirin. A P2Y12 inhibitor alone may also be considered instead of aspirin.

Antiplatelet therapy after a stent Standard case Aspirin + P2Y12 inhibitor Aspirin alone long term Stent 12 months With an anticoagulant 3 Anticoagulant plus clopidogrel Anticoagulant alone 3 drugs: about 1 week 12 months The treatment team sets duration and drugs.
Antiplatelet therapy in the first year and after.

Some people also need an anticoagulant, for example because of atrial fibrillation. With three such drugs, the bleeding risk is high. That is why triple therapy is usually limited to about one week. After that come the anticoagulant and one antiplatelet drug, preferably clopidogrel, for up to twelve months. After that, usually the anticoagulant remains alone.

Never stop on your own. A new stent is not yet fully covered by vessel wall, and platelets easily stick to it. If the protection stops too early, a clot can form in the stent, called stent thrombosis. It often causes another heart attack. Stents are not rejected the way an organ can be.

The most important side effect of all antiplatelet drugs is a higher risk of bleeding. Small bruises and slightly longer bleeding after shaving are common and usually harmless. Black, tarry stools or vomiting blood or material that looks like coffee grounds, however, can point to bleeding in the digestive tract. This needs medical attention right away. If the risk of such bleeding is increased, the ESC recommends stomach protection with dual antiplatelet therapy, a proton pump inhibitor.

Beta blockers, ACE inhibitors and more

Beta blockers shield the heart from stress hormones such as adrenaline. They lower heart rate and blood pressure, and the heart muscle needs less oxygen. They do not open narrowings. Typical side effects are a slow pulse and cold hands. They are clearly recommended if the pumping function of the left ventricle is reduced, that is with an LVEF of 40 percent or less, even without symptoms. With normal pumping function the benefit is less certain. Studies from 2025 such as REBOOT and BETAMI-DANBLOCK came to different results. Whether you then get a beta blocker is decided by your treatment team case by case.

A beta blocker is not stopped abruptly. The body has adjusted to the dampened effect of the stress hormones. If it suddenly disappears, pulse and blood pressure can overshoot, and chest tightness can occur. If necessary, it is tapered off slowly.

You can usually recognise ACE inhibitors by the ending "pril", for example ramipril or enalapril. Bisoprolol, ending in "olol", is a beta blocker, while candesartan, ending in "sartan", is an ARB. After an acute coronary syndrome, the ESC clearly recommends ACE inhibitors in certain cases. These are signs of heart failure, an LVEF of 40 percent or less, diabetes, high blood pressure or chronic kidney disease.

ACE inhibitors slow the breakdown of the messenger substance bradykinin. This can cause a dry, tickly cough. Then the treatment is often switched to an ARB, also called a sartan, such as candesartan or valsartan. ARBs act at a different point and hardly ever cause the cough. Both groups can raise potassium and affect kidney function. That is why potassium and kidney values such as creatinine are checked before starting and after dose changes.

Nitro spray in an emergency

Nitro spray is meant for an attack of chest tightness, called angina pectoris. Nitroglycerin quickly widens the blood vessels and relieves the heart. It only works briefly and does not replace long-term medicines.

  1. Sit down, because nitro can make you dizzy.
  2. Spray it into your mouth, ideally under the tongue. Do not inhale it and do not swallow straight away.
  3. If the symptoms do not ease within a few minutes, call the emergency services on 112 at once.

Do not drive yourself to hospital, and do not call your GP first. With new or unusually strong symptoms at rest, call 112 straight away.

Nitro lowers blood pressure. With markedly low blood pressure, that is systolic below 90 mmHg, it is contraindicated. High blood pressure, on the other hand, does not rule out nitro. The combination with PDE-5 inhibitors for erectile dysfunction is dangerous. After sildenafil or vardenafil, no nitrates should be given for 24 hours, after tadalafil for 48 hours. Anyone who has taken such a drug and develops chest tightness does not use nitro spray. They call 112 and tell the emergency team about the drug.

Interactions in everyday life

Grapefruit inhibits the enzyme CYP3A4 in the gut. Simvastatin and atorvastatin are broken down by this enzyme. With grapefruit juice, the drug level therefore rises, and with it the risk of muscle damage. The inhibition lasts a long time, so spacing the doses hardly helps. Rosuvastatin, pravastatin and pitavastatin are hardly broken down by these enzymes. For them, grapefruit plays hardly any role.

Ibuprofen temporarily occupies the same site on the platelets where aspirin is meant to act permanently. If you take it shortly before aspirin, aspirin cannot work properly there. Paracetamol does not show this interaction. Taken regularly together with aspirin, ibuprofen also raises the risk of stomach bleeding. Drugs of this group, the NSAIDs, also strain the heart and kidneys. So over the counter does not mean harmless. Agree on a suitable painkiller with your doctor or pharmacist.

With stomach protection, the drug matters too. Omeprazole and esomeprazole inhibit the enzyme CYP2C19, which activates clopidogrel. This combination is advised against. Pantoprazole is considered a possible alternative.

Staying on track

After an acute coronary syndrome, only about two thirds of people keep taking their medicines long term as prescribed. Yet the medicines only protect you while you take them. If you think you are not tolerating a medicine, talk to your doctor first. Many complaints can be solved with a different dose or a different drug.

A polypill can make regular intake easier. It combines several drugs in one tablet. In the SECURE trial it contained aspirin, ramipril and atorvastatin. It improved adherence and reduced major cardiovascular events. The ESC recommends considering a polypill. It does not contain a P2Y12 inhibitor, and checks of blood lipids and blood pressure are still needed.

Key points

  • Almost everyone takes an antiplatelet drug and a statin long term after a heart attack.
  • Statins act in the liver and stay, even once the target is reached.
  • Muscle complaints are often a nocebo effect, and a different dose or statin often helps.
  • If the statin is not enough, ezetimibe and then a PCSK9 inhibitor follow.
  • Dual antiplatelet therapy usually lasts twelve months, after which aspirin usually remains.
  • Beta blockers are clearly recommended with an LVEF of 40 percent or less.
  • If nitro does not help within a few minutes, call 112 at once.
  • Never stop a medicine on your own, talk to your doctor first.

Terms

Dual antiplatelet therapy
Aspirin together with a P2Y12 inhibitor, usually for twelve months.
Creatine kinase
Muscle enzyme in the blood that rises with muscle damage.
LVEF
Share of blood that the left ventricle pumps out with each beat.
Nocebo effect
Complaints that arise from expecting side effects.
P2Y12 inhibitor
Antiplatelet drug such as clopidogrel, prasugrel or ticagrelor.
Polypill
Tablet that combines several heart medicines.
Rhabdomyolysis
Rare, serious breakdown of muscle tissue.
Stent thrombosis
Clot in a stent that often causes a heart attack.

As of: November 18, 2026 (Leitlinienstand 2026)

Sources:

  • ESC/EAS guideline on dyslipidaemias 2019 and focused update 2025
  • ESC guideline on acute coronary syndromes 2023
  • German National Disease Management Guideline on chronic CHD, version 7 (2024), and patient version
  • Product information for Leqvio, Nilemdo, Efient, Brilique, clopidogrel, Nitrolingual
  • SAMSON trial (2020), REBOOT and BETAMI-DANBLOCK (2025), SECURE trial (2022)

This study guide was written with AI and checked against the sources.

Certifications & exams

Which exam comes next?

You can already practise for 51 exams, and 16 are up for a vote. See all certifications with their official information, cast your vote or suggest your exam.

See all certifications